Pfizer, Inc. · NYSE:PFE
Pfizer — European Society of Cardiology Congress 2018
17 slides from Pfizer's conference presentation, Aug 27, 2018
Slide 1: ESC 2018 Tafamidis Analyst Briefing
ESC 2018 Tafamidis Analyst Briefing August 27, 2018 1
Slide 2: Forward Looking Statements
Forward Looking Statements • This presentation includes forward-looking statements about, among other things, a potential indication for Tafamidis for the treatment of transthyretin cardiomyopathy and Pfizer’s rare disease portfolio, including their potential benefits, that are subject to substantia
Slide 3: John Young, Group President, Pfizer Innovative Health
John Young Group President, Pfizer Innovative Health 3
Slide 4: Pfizer Rare Disease: Growing Clinical Potential
Pfizer Rare Disease: Growing Clinical Potential *Pipeline status as of July31, 2018 †This compound is an investigational drug and is not approved by the FDA ‡Not approved in the United States. It is currently in registration in the United States 4 Duchenne Muscular Dystrophy (DMD)
Slide 5: Patients in Need: ATTR-CM is Currently Poorly Diagnosed
Patients in Need: ATTR-CM is Currently Poorly Diagnosed • ATTR-CM is a rare, progressive, and universally fatal disease associated with restrictive cardiomyopathy and progressive heart failure • Survival in untreated patients is 2.5 years (ATTRm) and 3.6 years (ATTRwt) post diagnosis* • The patient
Slide 6: Opportunity in Both Hereditary and Wild-Type ATTR-CM
Opportunity in Both Hereditary and Wild-Type ATTR-CM ■ Prevalence of transthyretin cardiomyopathy is presently unknown ■ Estimate 400K-500K ATTR-CM patients in developed markets* ● Less than 1% of people with the disease are diagnosed ● Approximately 15-25% of these patients are in the US Tafamidis
Slide 7: Tafamidis: A Potential New Treatment Option
Tafamidis: A Potential New Treatment Option ■ ATTR-CM is a significant health burden with both high mortality rates and rates of CV-related hospitalization ■ Currently ATTR-CM is poorly differentially diagnosed and there are no treatments approved for cardiomyopathy ■ Both Hereditary and Wild-Type p
Slide 8: Brenda Cooperstone, MD, Chief Development Officer, Pfizer Rare Disease
Brenda Cooperstone, MD Senior Vice President, Chief Development Officer, Pfizer Rare Disease 8
Slide 9: ATTR – Cardiomyopathy Has High Patient Impact
ATTR – Cardiomyopathy Has High Patient Impact ■ Transthyretin is an inherently unstable molecule in which mutation of TTR gene (Hereditary) or age (Wild-type) result in protein breakdown and amyloid deposits ■ ATTR-CM manifests > 60 yrs of age with signs and symptoms of heart failure ● Dyspnea on ex
Slide 10: ATTR-ACT Study: Significant Reduction in Primary Endpoint
ATTR-ACT Study: Significant Reduction in Primary Endpoint Tafamidis provided significant reduction in hierarchical combination of all- cause mortality and frequency of cardiovascular-related hospitalizations Pooled Tafamidis Placebo n=264 n=177 P-value from F-S method 0.0006 Patients alivea at Month
Slide 11: Reduction in All-cause Mortality with tafamidis
Reduction in All-cause Mortality with tafamidis 30% reduction in the risk of all-cause mortality with tafamidis compared with placebo* 33% reduction in the risk Analysis of All-Cause Mortality* of all-cause mortality with tafamidis compared with placebo for the analysis where heart transplant and im
Slide 12: Reduction in CV-related Hospitalizations with tafamidis
Reduction in CV-related Hospitalizations with tafamidis 32% reduction in the rate of CV-related hospitalization with tafamidis compared with placebo Pooled Tafamidis Placebo n=264 n=177 Total number (%) of patients with CV-related 138 (52.3) 107 (60.5) hospitalizations CV-related hospitalizations pe
Slide 13: Consistency Across Subgroups
Consistency Across Subgroups Tafamidis demonstrated consistency across subgroups as compared to placebo Higher hospitalization rate observed in NYHA Class III which may be attributable to longer survival during a more severe period of disease. 13
Slide 14: Functional Capacity and Quality of Life Endpoints Achieved
Functional Capacity and Quality of Life Endpoints Achieved Significant improvement in functional capacity and quality of life measures with tafamidis as compared to placebo 14
Slide 15: Well Tolerated in Both Oral Dose Groups
Well Tolerated in Both Oral Dose Groups Tafamidis was well tolerated across both oral 20mg and 80mg dose groups Pooled Tafamidis Placebo n=264 n=177 Mean number of TEAEs per patient 12.02 13.92 Patients with ≥1 TEAE, n (%) 260 (98.5) 175 (98.9) Patients with ≥1 treatment emergent SAE, n (%) 199 (75.
Slide 16: Conclusions
Conclusions ■ ATTR-CM is a highly under-diagnosed disease, and will require significant market development ■ Tafamidis is an investigational therapy for ATTR-CM, and is the only potential treatment for this disease that has completed a Phase 3 study designed to evaluate the safety and efficacy in AT
Slide 17: Pfizer Rare Disease
Pfizer Rare Disease
Pfizer — European Society of Cardiology Congress 2018 on 6ix